Skip to main content
TipRanks
Go Ultimate75% OFF

Solasia Pharma KK (4597) AI Stock Analysis

1 Followers
JP:4597

Solasia Pharma KK

(TSE/TYO:4597)

Select Model
Rating:33Underperform
Price Target:JPY 23.00â–¼(-4.17% Downside)
Action:reiterated
Date:11/14/26

Solasia Pharma scores poorly, driven primarily by weak financial performance: persistent operating losses, a TTM net loss of ¥830M on just ¥684M of revenue, and a cash burn of ¥1,127M that exceeds the loss itself. With equity of ¥1,345M being steadily consumed, further capital raises and dilution appear likely, even though the near-debt-free balance sheet limits solvency risk. Encouraging signs include ~76% TTM revenue growth, a return to a ~44% gross margin, and losses roughly a third of 2022 levels, but the gap to breakeven remains wide. Technicals reinforce caution, with the price below all key moving averages and negative MACD momentum, while a negative P/E and no dividend leave no valuation cushion. Note: the computed weighted average falls below the platform floor, so the score is set at the minimum of 37.

Positive Factors
Revenue RecoveryTTM revenue rebounded to 684M, up ~76%, showing meaningful recovery in the commercial base. If sustained, this higher revenue scale can improve fixed-cost absorption and create a stronger foundation for partner economics, product investment, and eventual operating leverage, although profitability has not yet followed.
Negative Factors
Severe UnprofitabilityA TTM net margin near -121%, together with deeply negative EBIT and net income, shows that the current revenue base does not cover the company’s cost structure. Persistent losses weaken financial resilience and leave the business without demonstrated operating leverage or a clear path to breakeven.

Solasia Pharma KK (4597) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%40%JP:4597-22.58%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.55B
Dividend Yield
―
Average Volume (3M)
77.14M
Price to Earnings (P/E)
-7.9
Beta (1Y)
1.33
Revenue Growth
109.82%
EPS Growth
61.98%
Country
Japan
Employees
22
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Solasia Pharma KK Business Overview & Revenue Model

Company Description

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil or...

How the Company Makes Money

Solasia Pharma generally makes money through (1) licensing and collaboration agreements for its drug candidates and/or marketed products, under which it may receive upfront payments, development and regulatory milestone payments, and sales-based roya...

Solasia Pharma KK Financial Statement Overview

Summary

Solasia remains a pre-profitability specialty pharma with deep structural weaknesses. The income statement (score 22) shows small, erratic revenue (¥684M TTM, +76%) and a TTM net loss of ¥830M, equal to roughly 120% of sales, despite a recovery in gross margin to about 44%. Cash flow (score 16) is the weakest link: operating cash flow has been negative in every period, with burn widening to ¥1,127M on a TTM basis — more than the net loss — indicating working capital drag and dependence on external funding. The balance sheet (score 45) is the relative bright spot, with minimal debt (¥69M vs. ¥1,345M equity, D/E ~0.05) and equity funding ~86% of assets, but equity is eroding from continuous losses (ROE ~-54%), implying likely further capital raises and shareholder dilution within roughly a year at the current burn rate.

Income Statement

22Negative

Balance Sheet

45Neutral

Cash Flow

16Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue684.00M429.00M316.00M617.00M1.09B559.00M
Gross Profit298.00M171.00M-10.00M-163.00M128.00M-121.00M
EBITDA-787.00M-822.00M-796.00M-639.00M-1.20B-1.92B
Net Income-830.00M-876.00M-1.94B-1.11B-2.55B-2.48B
Balance Sheet
Total Assets1.56B2.15B1.36B2.55B3.56B3.76B
Cash, Cash Equivalents and Short-Term Investments1.02B1.39B886.00M728.00M803.00M714.00M
Total Debt69.00M159.00M25.00M60.00M37.00M84.00M
Total Liabilities213.00M392.00M203.00M673.00M899.00M1.17B
Stockholders Equity1.34B1.75B1.16B1.88B2.66B2.59B
Cash Flow
Free Cash Flow-1.13B-847.00M-1.03B-359.00M-2.07B-2.48B
Operating Cash Flow-1.13B-847.00M-1.03B-359.00M-2.07B-2.47B
Investing Cash Flow-36.00M-81.00M02.00M-418.00M-164.00M
Financing Cash Flow319.00M1.43B1.18B275.00M2.57B361.00M

Solasia Pharma KK Technical Analysis

Technical Analysis SentimentNegative
Last Price24.00

Price Trends

50DMA27.84Negative
100DMA28.11Negative
200DMA29.16Negative

Market Momentum

MACD-1.25Positive
RSI42.10Neutral
STOCH36.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4597, the sentiment is Negative. The current price of 24.00 is below the 20-day moving average (MA) of 25.45, below the 50-day MA of 27.84, and below the 200-day MA of 29.16, indicating a bearish trend. The MACD of -1.25 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4597.

Solasia Pharma KK Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4597 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4574JP:457469NeutralJPY 12.82B30.32―1.29%13.72%-50.46%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4582JP:458248NeutralJPY 7.16B-0.82――-30.58%6.93%
JP:4539JP:453946NeutralJPY 5.57B-11.41―3.24%0.31%-194.72%
JP:4883JP:488342NeutralJPY 3.73B-1.41―――25.34%
JP:4892JP:489242NeutralJPY 5.08B-6.53――214.65%22.18%
JP:4597JP:459733UnderperformJPY 6.55B-7.89-53.06%―109.82%61.98%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:4597JP:4539JP:4574JP:4582JP:4883JP:4892Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4597 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4597Solasia Pharma KK24.00-7.00-22.58%
JP:4539Nippon Chemiphar Co., Ltd.1543.0068.974.68%
JP:4574Taiko Pharmaceutical Co., Ltd.256.00-35.00-12.03%
JP:4582Symbio Pharmaceuticals Limited71.00-33.00-31.73%
JP:4883Modalis Therapeutics Corporation31.00-36.00-53.73%
JP:4892Cyfuse Biomedical K.K.515.00-69.00-11.82%

Solasia Pharma KK Corporate Events

Solasia Updates Pipeline and Commercialization Activities

Nov 12, 2026

Solasia Pharma reported its third-quarter fiscal 2026 pipeline and product-status update. In China, partner MAAB began selling Sancuso in April 2026, completed the transition of sales operations from Lee’s Pharmaceutical, and received product shipmen...

Solasia Pharma Reports Higher Sales, Narrower Nine-Month Operating Loss

Nov 12, 2026

Solasia Pharma K.K. is listed on the Tokyo Stock Exchange’s Growth market under securities code 4597. It reported consolidated results for the nine months ended Sept. 30, 2026.Sales rose 277.3% year on year to ¥346 million, while operating loss narro...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026